Curasight is a clinical stage biotech company committed to improving both diagnosis and the treatment of certain types of cancer. Utilizing its cutting-edge uPAR Theranostic radionuclide platform the company is able to more accurately characterize the type and stage of the tumor using intelligent cancer imaging (uTRACE®) and with that knowledge, develop a more targeted, gentle and efficient approach to treatment (uTREAT®). The company was founded on a strong understanding of nuclear medicines, based on 10 years of research at Copenhagen’s University hospital, Rigshospitalet. Led by science and industry experts Curasight has built a pipeline of products which have been tested to Phase 2 of clinical development and which are robustly patent protected. Located in Copenhagen, Denmark, the company has strong international partnerships both in academia and industry and is firmly committed to using its pioneering technology to improve the lives of cancer patients globally.
Watch Curasight’s CSO and Co-Founder, Andreas Kjaer explain the company’s Theranostic approach